| Placebo + NBBM (n = 158) | CZP 200 mg Q2W + NBBM (n = 159) |
---|---|---|
Age (years), mean (SD) | 37.4 (10.8) | 37.3 (10.5) |
Female, n (%) | 82 (52) | 81 (51) |
HLA-B27 positive, n (%) | 132 (84) | 128 (81) |
Caucasian, n (%) | 148 (94) | 152 (96) |
Symptom duration (years), mean (SD) | 8.0 (7.5) | 7.8 (7.7) |
Time since first diagnosis (years), mean (SD) | 4.0 (5.4) | 3.6 (4.8) |
ASDAS, mean (SD) | 3.8 (0.9) | 3.8 (0.8) |
BASDAI score, mean (SD) | 6.8 (1.3) | 6.9 (1.4) |
BASFI score, mean (SD) | 5.4 (2.2) | 5.4 (2.1) |
BASMI score, mean (SD) | 2.8 (1.4) | 3.0 (1.3) |
CRP (mg/L), mean (SD) | 15.8 (17.7) | 15.8 (17.8) |
Elevated CRP at baseline (>ULN), n (%) | 83 (53) | 89 (56) |
MRI/CRP classification, n (%) | ||
 MRI+/CRP+ | 42 (27) | 45 (28) |
 MRI+/CRP− | 76 (48) | 74 (47) |
 MRI−/CRP+ | 39 (25) | 38 (24) |
Sacroiliac joint MRI SPARCC score, mean (SD) | 8.5 (12.3) | 7.8 (10.8) |
Sacroiliac joint MRI SPARCC score ≥2, n (%) | 129 (82) | 136 (86) |
Nocturnal spinal pain score, mean (SD) | 6.6 (2.1) | 6.6 (2.3) |
Past treatment,a n (%) | ||
 NSAIDs | 144 (91) | 143 (90) |
 DMARDsb | 46 (29) | 44 (28) |
 Tumour necrosis factor inhibitors | 11 (7) | 7 (4) |
Concomitant treatment, n (%) | ||
 NSAIDs | 138 (87) | 138 (87) |
 DMARDs | 48 (30) | 55 (35) |
 Systemic corticosteroids | 26 (17) | 27 (17) |